Idorsia announces the first patient recruited into REACT - the Phase 3 registration study with
Idorsia Pharmaceuticals Ltd. /
Idorsia announces the first patient recruited into REACT - the Phase 3
registration study with clazosentan
. Verarbeitet und übermittelt durch West Corporation.
Für den Inhalt der Mitteilung ist der Emittent verantwortlich.
* REACT assesses the efficacy and safety of intravenous clazosentan for the
prevention of clinical deterioration due to vasospasm-related delayed
cerebral ischemia following aneurysmal subarachnoid hemorrhage (aSAH)
* On June 18, 2018, Idorsia announced the plans for REACT and held an investor
webcast, please refer to the documentation on our corporate website for more
Allschwil, Switzerland - February 5, 2019
Idorsia Ltd (SIX: IDIA) today announced that the first patient has been included
into REACT, a Phase 3 registration study to investigate the efficacy and safety
of clazosentan for the prevention of clinical deterioration due to vasospasm-
related delayed cerebral ischemia in patients following an aneurysmal
Guy Braunstein, MD and Head of Global Clinical Development, commented:
"REACT builds on the learnings from previous clinical studies with clazosentan,
which have served to identify the optimal treatment dose for Phase 3 evaluation
and the characteristics and management of the patients that are most likely to
benefit from this treatment. It is very satisfying to have achieved the
milestone of first patient included into the study. It's now full steam ahead to
recruit 400 patients."
Notes to the editor
Several studies have built our understanding of clazosentan, an intravenous
endothelin receptor antagonist, regarding its impact on preventing or reversing
cerebral vasospasm. These studies suggest that clazosentan has the potential to
prevent vasospasm-related delayed cerebral ischemia and to decrease the need for
invasive neurovascular intervention. Clazosentan was granted orphan status in
Europe in 2003 and in the US in 2006.
About the REACT study
REACT is a prospective, multi-center, double-blind, randomized, placebo-
controlled, parallel-group, Phase 3 study to assess the efficacy and safety of
clazosentan in preventing clinical deterioration due to vasospasm-related
delayed cerebral ischemia, in adult patients with aSAH. Approximately 400
patients, regardless of whether their hemorrhage has been treated with surgical
clipping or endovascular coiling are expected to be enrolled. Patients will be
enrolled from 100 trial sites across 15 countries and will be randomized to
either 15 mg/hr clazosentan or placebo for a treatment period of up to 14 days.
The study is expected to run for over two years.
REACT will enroll aSAH patients identified as being at high-risk of developing
delayed ischemic neurological deficit because of high volume of their
hemorrhage, as assessed by CT scan on hospital admission. Patients experiencing
asymptomatic (or minimally symptomatic) moderate to severe cerebral vasospasm
within 14 days of the aneurysm-rupture may also be included.
About aneurysmal subarachnoid hemorrhage and cerebral vasospasm
Aneurysmal subarachnoid hemorrhage (aSAH) is a sudden life-threatening bleeding
occurring in the subarachnoid space. It is caused by the rupture of an aneurysm
- a weak, bulging spot on the wall of a cerebral artery. Emergency repair
(endovascular coiling or microsurgical clipping) is required to stop the
The bleeding and the release of a vasoconstrictor, endothelin, by the
neighboring vascular endothelium, causes many patients to experience vasospasm
(constriction of arteries in the brain). This diminishes blood flow to the brain
and as a consequence, about one third of patients experience worsening of their
neurological condition. Patients with thick and diffuse blood clots are at a
significantly higher risk of experiencing cerebral vasospasm. Today, patients
with vasospasm are typically treated with hemodynamic therapy, or more invasive
neurovascular intervention such as balloon angioplasty or intra-arterial
administration of vasodilators.
* Macdonald R L, et al. Stroke. 2012; 43(6):1463-9.
* Macdonald R L, et al. The Lancet. Neurology, 2011; 10(7):618-625.
* Macdonald R L, et al. Stroke 2008; 39:3015-3021.
* Vajkoczy P, et al. Journal of Neurosurgery 2005; 103:9-17.
* Roux S. et al. J Pharmacol Exp Ther 1997; 283:1110-1118.
Idorsia Ltd is reaching out for more - We have more ideas, we see more
opportunities and we want to help more patients. In order to achieve this, we
will develop Idorsia into one of Europe's leading biopharmaceutical companies,
with a strong scientific core.
Headquartered in Switzerland - a biotech-hub of Europe - Idorsia is specialized
in the discovery and development of small molecules, to transform the horizon of
therapeutic options. Idorsia has a broad portfolio of innovative drugs in the
pipeline, an experienced team, a fully-functional research center, and a strong
balance sheet - the ideal constellation to bringing R&D efforts to business
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017
and has over 700 highly qualified specialists dedicated to realizing our
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 (0) 58 844 10 10
The above information contains certain "forward-looking statements", relating to
the company's business, which can be identified by the use of forward-looking
terminology such as "estimates", "believes", "expects", "may", "are expected
to", "will", "will continue", "should", "would be", "seeks", "pending" or
"anticipates" or similar expressions, or by discussions of strategy, plans or
intentions. Such statements include descriptions of the company's investment and
research and development programs and anticipated expenditures in connection
therewith, descriptions of new products expected to be introduced by the company
and anticipated customer demand for such products and products in the company's
existing portfolio. Such statements reflect the current views of the company
with respect to future events and are subject to certain risks, uncertainties
and assumptions. Many factors could cause the actual results, performance or
achievements of the company to be materially different from any future results,
performances or achievements that may be expressed or implied by such forward-
looking statements. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those described herein as anticipated, believed,
estimated or expected.
This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content,
accuracy and originality of the information contained therein.
Source: Idorsia Pharmaceuticals Ltd. via GlobeNewswire